NuCana PLC (NCNA)
1.49
-0.06
(-3.87%)
USD |
NASDAQ |
Nov 15, 16:00
1.49
0.00 (0.00%)
After-Hours: 20:00
NuCana Research and Development Expense (TTM): 35.08M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 35.08M |
| March 31, 2024 | 31.50M |
| December 31, 2023 | 31.17M |
| September 30, 2023 | 38.15M |
| June 30, 2023 | 37.43M |
| March 31, 2023 | 40.53M |
| December 31, 2022 | 44.93M |
| September 30, 2022 | 43.75M |
| June 30, 2022 | 47.43M |
| March 31, 2022 | 51.29M |
| December 31, 2021 | 50.62M |
| September 30, 2021 | 46.81M |
| June 30, 2021 | 42.35M |
| March 31, 2021 | 37.71M |
| Date | Value |
|---|---|
| December 31, 2020 | 33.32M |
| September 30, 2020 | 29.46M |
| June 30, 2020 | 27.52M |
| March 31, 2020 | 27.13M |
| December 31, 2019 | 25.19M |
| September 30, 2019 | 24.50M |
| June 30, 2019 | 22.87M |
| March 31, 2019 | 23.02M |
| December 31, 2018 | 22.50M |
| September 30, 2018 | 21.58M |
| June 30, 2018 | 30.56M |
| March 31, 2018 | 26.18M |
| December 31, 2017 | 23.03M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
25.19M
Minimum
Dec 2019
51.29M
Maximum
Mar 2022
37.97M
Average
37.71M
Median
Mar 2021
Research and Development Expense (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | 143.17M |
| Biodexa Pharmaceuticals PLC | -- |
| Autolus Therapeutics PLC | 129.68M |
| Mereo BioPharma Group PLC | 16.91M |
| Bicycle Therapeutics PLC | 167.88M |